Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Azitra Q3 2026 Results: Net Loss of $2.95M, Loss Widens

Azitra, Inc. reported a net loss of $10.2 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year period. The company significantly strengthened its cash position to $3.8 million through a $10.4 million private placement and warrant exercises, while continuing to invest heavily in research and development for its synthetic biology dermatology platform.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-2.9-2.8
Net income-2.9-2.8
EPS (diluted, $ a share)$-0.29$-6.71

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NYSE: AZTR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Azitra, Inc.: key numbers

Share price
$0.6270Close, Nov 16
Market cap
$3.8M
Shares outstanding
6.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Azitra, Inc.

All →
4:16 PM ET 8-K
Financial Results

Azitra Financial Results

Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.

Term
Q3 2026

“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”

Francisco Salva, Chief Executive Officer

“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”

Francisco Salva, Chief Executive Officer
8:41 AM ET 8-K
Clinical Trial Data

Azitra Clinical Trial Data

Azitra announced positive ex vivo human skin model data for its ATR-COSF program, showing a 56% reduction in wrinkles and improved skin elasticity. The company plans to initiate a first-in-human study for the filaggrin-based topical cosmetic with initial results expected by year-end 2026. Additionally, the company provided updates on its ATR-04 Phase 1/2 trial, which has been expanded to include patients with rashes from KRAS and MEK inhibitors.

8:36 AM ET 8-K
Business Update

Azitra Business Update

Azitra has amended its Phase 1/2 clinical trial protocol for ATR-04 to expand patient eligibility to include those with rashes caused by KRAS and MEK inhibitors, as well as NF1 patients. The company also shortened required washout periods for antibiotics and steroids to accelerate patient recruitment and enrollment for Cohort 2 of the study.

8:51 AM ET 8-K
Deal Termination

Azitra Deal Termination with A.G.P./Alliance Global Partners

Azitra, Inc. announced it has decided to suspend and not utilize its at-the-market (ATM) offering program with A.G.P./Alliance Global Partners for the foreseeable future. The company cited its current capital resources, upcoming milestones, and the dilutive effect of equity issuances as reasons for the decision. Separately, the company released positive ex vivo study data for its ATR-COSF cosmetic program showing improvements in skin elasticity and fine lines.

Counterparty
A.G.P./Alliance Global Partners
4:16 PM ET 8-K
Reverse Stock Split

Azitra Reverse Stock Split

Azitra, Inc. has filed a certificate of amendment to effectuate a 1-for-10 reverse stock split of its common stock, effective October 26, 2026. The split aims to consolidate every 10 shares into one share to adjust the trading price on the NYSE American. No fractional shares will be issued, with stockholders receiving cash payments in lieu of fractional interests.

8:11 AM ET 8-K
Clinical Trial Data

Azitra Clinical Trial Data

Azitra, Inc. has completed Cohort 1 of its Phase 1/2 clinical trial for ATR-04, a live biotherapeutic candidate for treating skin rash associated with EGFR inhibitors. Following a safety review committee clearance, the company is proceeding to enroll approximately 24 patients in Cohort 2 to further evaluate safety, tolerability, and preliminary efficacy.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.